Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q3 FY23 results · Oct–Dec 2022
Glenmark Pharmaceuticals reported revenue from operations of ₹3,463.86 crore (up 9.2% from Q3 FY22) and net profit of ₹290.76 crore (up 21.3% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,463.86 | 3,173.41 | +9.2% | 3,375.25 | +2.6% |
| Other income | 76.42 | 13.89 | +449.9% | 97.43 | −21.6% |
| Total income | 3,540.27 | 3,187.31 | +11.1% | 3,472.68 | +1.9% |
| Profit before tax | 471.00 | 343.04 | +37.3% | 480.21 | −1.9% |
| Net profit for the period | 290.76 | 239.75 | +21.3% | 278.67 | +4.3% |
| EPS, basic (₹) | 9.66 | 7.86 | +22.9% | 9.23 | +4.7% |
| Net margin (%) | 8.4 | 7.6 | 8.3 |
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,161.47 | 2,033.05 | +6.3% | 2,208.21 | −2.1% |
| Other income | 89.73 | 216.74 | −58.6% | 316.73 | −71.7% |
| Total income | 2,251.20 | 2,249.80 | +0.1% | 2,524.94 | −10.8% |
| Profit before tax | 589.13 | 636.65 | −7.5% | 600.52 | −1.9% |
| Net profit for the period | 430.50 | 548.52 | −21.5% | 423.15 | +1.7% |
| EPS, basic (₹) | 15.26 | 19.44 | −21.5% | 15.00 | +1.7% |
| Net margin (%) | 19.9 | 27.0 | 19.2 |
Consolidated
- Filed with BSE
- 11 Feb 2023, 15:39 IST
- Board meeting
- 10 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Feb 2023, 15:39 IST
- Board meeting
- 10 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE